482 related articles for article (PubMed ID: 11857288)
21. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.
Nückel H; Dürig J; Dührsen U
Ann Hematol; 2003 Aug; 82(8):481-486. PubMed ID: 12910375
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
23. ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas.
Hänel M; Kröger N; Hoffknecht MM; Peters SO; Metzner B; Fiedler F; Braumann D; Schubert JC; Illiger HJ; Hänel A; Krüger WH; Zeller W; Weh HJ; Hossfeld DK; Zander AR
Ann Hematol; 2000 Jun; 79(6):304-11. PubMed ID: 10901609
[TBL] [Abstract][Full Text] [Related]
24. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
[TBL] [Abstract][Full Text] [Related]
26. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
27. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Wang WS; Tzeng CH; Chiou TJ; Liu JH; Hsieh RK; Yen CC; Chen PM
Jpn J Clin Oncol; 1997 Jun; 27(3):154-7. PubMed ID: 9255269
[TBL] [Abstract][Full Text] [Related]
28. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
29. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
Choi CW; Paek CW; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
J Korean Med Sci; 2002 Oct; 17(5):621-4. PubMed ID: 12378012
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B; Thomare P; Delande E; Moynard J; Gastinne T; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Boudreault JS; Perrin F; Lok A; Guillaume T; Garnier A; Peterlin P; Gallas P; Chevallier P; Moreau P; Le Gouill S
Ann Hematol; 2017 Jun; 96(6):943-950. PubMed ID: 28374163
[TBL] [Abstract][Full Text] [Related]
31. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Giles FJ; O'Brien SM; Santini V; Gandhi V; Plunkett W; Seymour JF; Robertson LE; Kantarjian HM; Keating MJ
Leuk Lymphoma; 1999 Dec; 36(1-2):57-65. PubMed ID: 10613450
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
Lazzarino M; Orlandi E; Montillo M; Tedeschi A; Pagnucco G; Astori C; Corso A; Brusamolino E; Simoncini L; Morra E; Bernasconi C
Ann Oncol; 1999 Jan; 10(1):59-64. PubMed ID: 10076723
[TBL] [Abstract][Full Text] [Related]
33. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
34. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
35. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Rao R; Shammo JM; Enschede SH; Porter C; Adler SS; Venugopal P; Gregory SA
Clin Lymphoma; 2005 Jun; 6(1):26-30. PubMed ID: 15989703
[TBL] [Abstract][Full Text] [Related]
36. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
37. Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma.
Goss G; Szer J; Basser R; Fox R; Grigg A
Aust N Z J Med; 1997 Jun; 27(3):323-9. PubMed ID: 9227818
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
[TBL] [Abstract][Full Text] [Related]
39. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
Oztürk MA; Barişta I; Altundağ MK; Türker A; Yalçin S; Celik I; Güllü I; Güler N; Ozişik Y; Kars A; Kansu E; Baltali E; Tekuzman G
Chemotherapy; 2002 Dec; 48(5):252-8. PubMed ID: 12476042
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
